1-乙基-5-苯基咪唑 | 24463-50-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 1-乙基-5-苯基咪唑
• 英文名称: 1-ethyl-5-phenylimidazole
• 英文别名: 1-Ethyl-5-phenyl-1h-imidazole
• CAS: 24463-50-1
• 化学式: C₁₁H₁₂N₂
• mdl: MFCD09033084
• 分子量: 172.23
• InChiKey: AIUBMIGBGSCTRR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.181
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2933290090

反应信息

• 作为反应物：
  描述：

  1-乙基-5-苯基咪唑 在 potassium phosphate 、 N-溴代丁二酰亚胺(NBS) 、 methanesulfonato(2-dicyclohexylphosphino-2’,6’-di-i-propoxy-1,1’-biphenyl)(2’-methylamino-1,1‘-biphenyl-2-yl)palladium(II) 作用下， 以 1,4-二氧六环 、 水 、 乙腈 为溶剂， 反应 3.0h， 生成 3-[6-(1-ethyl-5-phenylimidazol-4-yl)-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione
  参考文献：
  名称：

  WO2024054832A1

  摘要：

  公开号：
• 作为产物：
  描述：

  N-[(E)-2-phenyl-1-(toluene-4-sulfonyl)-vinyl]-formamide 在 三乙胺 、 三氯氧磷 作用下， 以 甲醇 、 乙二醇二甲醚 为溶剂， 反应 1.0h， 生成 1-乙基-5-苯基咪唑
  参考文献：
  名称：

  Kikuchi, Masamichi; Kuwano, Eiichi; Nakashima, Yukiko, Bioscience, Biotechnology and Biochemistry, 1992, vol. 56, # 1, p. 161 - 162

  摘要：

  DOI：

文献信息

• [EN] TDO2 AND IDO1 INHIBITORS<br/>[FR] INHIBITEURS DE TDO2 ET IDO1
  申请人：GENENTECH INC

  公开号：WO2019005559A1

  公开（公告）日：2019-01-03

  Presently provided are inhibitors of cellularly expressed TD02 and IDO1, and pharmaceutical compositions thereof, useful for modulating an activity of tryptophan 2,3 dioxygenase and indoleamine 2,3-dioxygenase 1; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; and treating tumor-specific immunosuppression associated with cancer.

  目前提供了细胞表达的TD02和IDO1的抑制剂，以及与之相关的药物组合物，用于调节色氨酸2,3双氧化酶和吲哚胺2,3-双氧酶1的活性；治疗免疫抑制；治疗受益于抑制色氨酸降解的医疗状况；增强包括给予抗癌药物在内的抗癌治疗的有效性；以及治疗与癌症相关的肿瘤特异性免疫抑制。
• IDO Inhibitors
  申请人：Mautino Mario R.

  公开号：US20110136796A1

  公开（公告）日：2011-06-09

  Presently provided are compounds according to the formula (I) or (II), and pharmaceutical compositions comprising the compounds, wherein R 1 , R 4 , and R 5 are defined herein. Such compounds and compositions are useful for modulating an activity of indoleamine 2,3-dioxygenase; treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression; treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine -2,3-dioxygenase; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; treating tumor-specific immunosuppression associated with cancer; and treating immunosupression associated with an infectious disease.

  目前提供了按照公式(I)或(II)定义的化合物以及含有这些化合物的药物组合物，其中R1、R4和R5的定义在此处。这些化合物和组合物对于调节吲哚胺2,3-二氧化酶的活性；治疗吲哚胺2,3-二氧化酶(IDO)介导的免疫抑制；治疗从抑制吲哚胺-2,3-二氧化酶的酶活性中获益的医疗状况；增强包括给予抗癌剂的抗癌治疗的有效性；治疗与癌症相关的肿瘤特异性免疫抑制；以及治疗与传染性疾病相关的免疫抑制具有用处。
• Synthesis and structure–Activity relationship of 2-amino-3-heteroaryl-quinoxalines as non-peptide, small-Molecule antagonists for interleukin-8 receptor
  作者：Jie Jack Li、Kenneth G Carson、Bharat K Trivedi、Wen Song Yue、Qing Ye、Roberta A Glynn、Steven R Miller、David T Connor、Bruce D Roth、Jay R Luly、Joseph E Low、David J Heilig、Weixing Yang、Shixin Qin、Stephen Hunt

  DOI：10.1016/s0968-0896(03)00399-7

  日期：2003.8

  Interleukin-8 modulation is implicated in many inflammatory and cancer diseases. Starting from a mass-screening hit, the synthesis and structure-activity relationship of 2-amino-3-heteroarylquinoxalines as non-peptide, small molecule interleukine-8 receptor antagonists have been developed. The optimized derivatives, PD 0210293 (13y) and PD 0220245 (13r), show inhibition of both IL-8 receptor binding and IL-8-mediated neutrophil chemotaxis. (C) 2003 Elsevier Ltd. All rights reserved.
• IDO INHIBITORS
  申请人：Newlink Genetics

  公开号：EP2291187A2

  公开（公告）日：2011-03-09
• Pyrimidine derivatives for the prevention of hiv infection
  申请人：Heeres Jan

  公开号：US20070021449A1

  公开（公告）日：2007-01-25

  This invention concerns the use of a compound for the manufacture of a medicament for the prevention of HIV infection via sexual intercourse and related intimate contact between partners, wherein the compound is a compound of formula (I) a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof, wherein the ring containing -a 1 =a 2 -a 3 =a 4 - and -b 1 =b 2 -b 3 =b 4 - represents phenyl, pyridyl, pyrimidinyl, pirazinyl, pyridazinyl; and pharmaceutical compositions comprising them.